ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Sino Biopharm Subsidiary Grows Innovati
ScripOncology clinical trials are becoming costlier in China and are already roughly 30% more than in the US, according to one industry insider. The conventional thinking that such costs in the US remain m